yahoo_financeOriginal article
Update: Kailera Says Oral Small Molecule KAI-7535 Achieves Up to 11% Weight Loss in Phase 3 Trial; Shares Fall
Phase 3positiveKAI-7535Negative
AI Analysis
Summary
Kailera's oral small molecule KAI-7535 achieved up to 11% weight loss in Phase 3 trial, though the stock declined following the announcement.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
achieved up to 11% weight loss
Importance:7/10
Sentiment:
-0.30
phase_3_resultsweight_losssmall_moleculeoralstock_decline
Related Companies
Read the original article
Published by yahoo_finance on July 7, 2026 6:49 PM